Extensive Stage Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

February 22 17:40 2023
Extensive Stage Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including Extensive Stage Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the Extensive Stage Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Extensive Stage Small Cell Lung Cancer emerging drugs, the Extensive Stage Small Cell Lung Cancer pipeline analysis report provides a 360° view of the Extensive Stage Small Cell Lung Cancer pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Extensive Stage Small Cell Lung Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Extensive Stage Small Cell Lung Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Extensive Stage Small Cell Lung Cancer clinical trials studies, Extensive Stage Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, Extensive Stage Small Cell Lung Cancer (ESCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

 

  • DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.

 

  • The leading Extensive Stage Small Cell Lung Cancer companies such as Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine,  Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics,  Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company,  Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others.

 

  • Promising Extensive Stage Small Cell Lung Cancer pipeline therapies includes LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, AK112, RP12146, Sintilimab, and others.

 

  • The Extensive Stage Small Cell Lung Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Extensive Stage Small Cell Lung Cancer R&D. The Extensive Stage Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve Extensive Stage Small Cell Lung Cancer.

 

To explore more information on the latest breakthroughs in the Extensive Stage Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook

 

Extensive Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (ESCLC) (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.

 

Latest Developmental Activities in the Extensive Stage Small Cell Lung Cancer Treatment Landscape

 

  • In April 2022, Shanghai Henlius Biotech, announced that the New Drug Application of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of Extensive-stage Small Cell Lung cancer (ES-SCLC) has been accepted by the National Medical Products Administration (NMPA). Henlius has also planned to file MAA in the EU in 2022. In April 2022, FDA has granted Orphan-Drug Designation for HANSIZHUANG for the treatment of SCLC, benefiting the continuous development of HANSIZHUANG.

 

  • In March 2022, Akesobio entered into a collaboration agreement with Shenzhen Chipscreen Biosciences to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L) 1 inhibitor as first-line treatment.

 

  • In October 2021, Jiangsu Hengrui Pharmaceuticals reported positive data of a Phase III study, demonstrating that the investigational anti-PD-L1 mAb adebrelimab (SHR-1316) in combination with etoposide and carboplatin (EC) compared with placebo in combination with EC met the primary endpoint of overall survival (OS) as first-line treatment for extensive-stage small cell lung cancer. Hengrui has submitted a pre-New Drug Application meeting request to China National Medical Products Administration based on the positive data.

 

  • BioNTech is evaluating BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer.  In July 2021, BNT411 demonstrated an acceptable safety profile at all doses tested as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.

 

  • In March 2021, China’s National Medical Products Administration cleared Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. 

 

For further information, refer to the detailed Extensive Stage Small Cell Lung Cancer Unmet Needs, Extensive Stage Small Cell Lung Cancer Market Drivers, and Extensive Stage Small Cell Lung Cancer Market Barriers, click here for Extensive Stage Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

Extensive Stage Small Cell Lung Cancer Emerging Drugs Profile

 

  • LY 2510924: Eli Lilly and Company

LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY-2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

 

  • Tiragolumab: Genentech

Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tiragolumab works as an immune amplifier, by potentially enhancing the body’s immune response. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell anti-tumor activity. It is in phase 3 stage of development for the treatment of Extensive-Stage Small Cell Lung Cancer.

 

Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Extensive Stage Small Cell Lung Cancer (ESCLC). The companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

Extensive Stage Small Cell Lung Cancer Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

 

Molecule Type

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Request a sample and discover the recent advances in Extensive Stage Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Extensive Stage Small Cell Lung Cancer Treatment Landscape

 

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report

 

  • Coverage- Global

 

  • Extensive Stage Small Cell Lung Cancer Companies- Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine,  Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics,  Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company,  Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others

 

  • Extensive Stage Small Cell Lung Cancer Pipeline Therapies- LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, AK112, RP12146, Sintilimab, and others.

 

  • Extensive Stage Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Extensive Stage Small Cell Lung Cancer Market Drivers and Extensive Stage Small Cell Lung Cancer Market Barriers, click here @ Extensive Stage Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Tiragolumab: Genentech
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. LY 2510924: Eli Lilly and Company
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
  17. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
  18. Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
  19. Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
  20. Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
  21. Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
  22. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
  23. Appendix

 

Got Queries? Find out the related information on Extensive Stage Small Cell Lung Cancer Mergers and acquisitions, Extensive Stage Small Cell Lung Cancer Licensing Activities @ Extensive Stage Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services